
|Videos|January 11, 2018
Advances in Breast Cancer Screening, Diagnosis
Author(s)Sarah M. Friedewald, MD
This video highlights recent studies advancing the field of breast cancer screening and diagnosis, including the potential need for increased surveillance in patients with false positives and patient access to mammography.
Advertisement
In this video, Sarah M. Friedewald, MD, of the Northwestern Medicine Feinberg School of Medicine in Chicago, highlights recent studies advancing the field of breast cancer screening and diagnosis, including patient access to mammography and the potential need for increased surveillance in patients with false positives, as they may be at increased risk for breast cancer.
Friedewald was a discussant for a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Advertisement
Related Content
Advertisement

ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD


109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD

110 Randomized Phase II Trial Evaluating Three Anti-diarrheal Prophylaxis Strategies in Patients (pts) with HER2+/HR+ Early Breast Cancer (EBC) Treated with Extended Adjuvant Neratinib (Dianer Geicam/2018-06)
ByJ. Gil-Gil,M. Ruíz-Borrego,E. Carrasco,Y. Izarzugaza,C. Martínez-Vila,E. Galve,B. López-Barajas,E. Adrover,T. Silovski,M. Valero-Arbizu,Á. Guerrero-Zotano,S. González-Santiago,M. Echarri,A. Cano-Jiménez,A. Vethencourt-Casado,M. De Laurentis,C. Bueno-Muiño,B. Adamo,R. Andrés,C. Villanueva,F. Rojo,M. Casas,P. Wilson,J. Suissa,V. Adams,M. Martin

Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
Yoga Could Alter Cancer-Related Fatigue Levels Across Solid Tumors
3
109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
4
Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC
5


















































